Viking's VK2735 Phase 1 shows up to 7.8% mean weight loss; Phase 2 obesity trial planned mid-2023

Viking Therapeutics, Inc.

Placebo-adjusted mean weight loss up to 6.0% (7.8% from baseline) after 28 days of weekly dosing.
No hypoglycemia reported; 98% of adverse events mild/moderate; one SAE (gallstone obstruction) in a subject with history of cholelithiasis.
VK2735 half-life ~170-250 hours; plans to evaluate higher doses with longer titration in Phase 2.
Phase 2 trial in obesity expected to initiate in mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.